Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma
- PMID: 20040052
- DOI: 10.1111/j.1478-3231.2009.02194.x
Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma
Abstract
Cell-mediated immune responses play an important role in the control of tumour growth. CD4 and CD8 T cells recognise tumour antigens presented via major histocompatibility complex molecules of antigen presenting cells and develop into effector cells with the ability to identify and kill tumour cells. Here, we re-examine the adaptive immune response to tumour antigens expressed by hepatocellular carcinoma (HCC) and discuss approaches that could be applied in future T-cell-based immunotherapy schedules to induce a potent and effective antitumour immunity. Moreover, we discuss cytotoxic T lymphocyte and Th1 responses to tumour antigens in patients with HCC and evaluate the effects of conventional treatments on antitumour T-cell responses.
Similar articles
-
alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.Hum Immunol. 2007 May;68(5):334-41. doi: 10.1016/j.humimm.2007.01.008. Epub 2007 Feb 21. Hum Immunol. 2007. PMID: 17462500
-
Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.Liver Int. 2006 Apr;26(3):369-79. doi: 10.1111/j.1478-3231.2005.01235.x. Liver Int. 2006. PMID: 16584401
-
Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.Oncol Rep. 2007 Jul;18(1):279-85. Oncol Rep. 2007. PMID: 17549380
-
Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.Expert Rev Anticancer Ther. 2009 Oct;9(10):1499-510. doi: 10.1586/era.09.103. Expert Rev Anticancer Ther. 2009. PMID: 19828011 Review.
-
Is there a role for immunotherapy in hepatocellular carcinoma?Dig Liver Dis. 2006 Apr;38(4):221-5. doi: 10.1016/j.dld.2005.12.004. Epub 2006 Feb 3. Dig Liver Dis. 2006. PMID: 16461021 Review.
Cited by
-
Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.Vaccine. 2015 Mar 3;33(10):1256-66. doi: 10.1016/j.vaccine.2015.01.037. Epub 2015 Jan 25. Vaccine. 2015. PMID: 25629522 Free PMC article.
-
Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway.BMC Infect Dis. 2021 Jan 12;21(1):56. doi: 10.1186/s12879-020-05713-0. BMC Infect Dis. 2021. PMID: 33435880 Free PMC article.
-
Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach.Front Physiol. 2011 Jul 11;2:32. doi: 10.3389/fphys.2011.00032. eCollection 2011. Front Physiol. 2011. PMID: 21808621 Free PMC article.
-
Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma.Dig Dis. 2012;30(5):477-82. doi: 10.1159/000341695. Epub 2012 Oct 24. Dig Dis. 2012. PMID: 23108303 Free PMC article. Review.
-
Immunotherapy for hepatocellular carcinoma: Current and future.World J Gastroenterol. 2019 Jun 28;25(24):2977-2989. doi: 10.3748/wjg.v25.i24.2977. World J Gastroenterol. 2019. PMID: 31293335 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials